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Autoimmunity is highly coincident with immunodeficiency. In a small but growing num-
ber of primary immunodeficiencies, autoantibodies are diagnostic of a given disease and
implicated in disease pathogenesis. In order to improve our understanding of the role
of autoantibodies in immunodeficiencies and to discover novel autoantibodies, new pro-
teomic tools are needed. Protein microarrays have the ability to screen for reactivity to
hundreds to many thousands of unique autoantigens simultaneously on a single chip using
minimal serum input. Here, we review different types of protein microarrays and how they
can be useful in framing the study of primary and secondary immunodeficiencies.
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INTRODUCTION
Primary immunodeficiency is integrally tied to autoimmunity.
A frequent misconception is that the immune system is a one-
dimensional balance: that immunodeficiency is a state of immune
system under-activation and autoimmunity is a state of over-
activation. Although appealing theoretically, the large majority of
diseases in either category contradict such a model. In fact, in many
immunodeficiencies, autoimmunity is a persistent and dangerous
clinical problem (1, 2). Conversely, in many autoimmune diseases,
patients are more susceptible to both common and opportunis-
tic infections (3). These clinical observations suggest a complex
relationship between autoimmunity and immunodeficiency.
Measurement of circulating autoantibodies has been a critical
tool for defining and understanding clinical autoimmune disease.
From diagnostic and research perspectives, autoantibodies have
the advantage of being highly stable secreted molecules present
in blood at high concentrations. Additionally, they are plausible
drivers of tissue damage (4). Unlike T cell receptors, the other
mechanism by which adaptive immune cells generate specificity,
antibodies directly recognize their cognate antigen without requir-
ing antigen processing and presentation. These advantages make
antibodies widely used reagents with applications ranging from
biomarkers to therapeutics.
Historically, the first clinically relevant autoantibodies were
discovered in the mid-20th century following observations of
the morphological effects of serum on leukocytes (5, 6). Over
the remainder of the 20th century, new techniques emerged
which allowed for greater ease of use and specificity. Techniques
such as the radiobinding assay, western blot, and enzyme-linked
immunosorbent assay (ELISA) allowed for the detection of anti-
bodies against a specific antigen or epitope, rather than against
complex mixtures such as cell lysates (Table 1).
Each of these tools, however, required an a priori hypothesis
or knowledge of the autoantigen. In a way, autoantibody profiling
has been limited to single targets in a manner analogous to the
limitations of the study of gene expression prior to DNA microar-
rays and high-throughput sequencing. To allow for the study of
autoantibodies from a proteomic perspective, highly multiplexed
tools are needed.
Here, we briefly review assays pertinent to the detection and
study of autoantibodies. We then describe different types of
autoantigen protein microarrays and discuss the advantages and
disadvantages of each platform. We also review the literature of
autoantibodies in immunodeficiency and discuss the role of pro-
tein microarrays in addressing unanswered questions. Lastly, we
close with theoretical insights into the autoantibody response from
a systems perspective made possible by the study of autoantibodies
with microarrays.
PROTEIN MICROARRAY TECHNOLOGIES
DNA microarrays revolutionized the study of gene expression. The
first generation of DNA microarrays was fabricated using a robotic
printer to spot cDNA nucleotide features directly onto a planar sur-
face, while some newer technologies use inkjet printing or maskless
photolithography processes. In either case, fluorescently labeled
cDNAs are incubated and allowed to hybridize to complementary
features on the array. Arrays are washed, and feature binding is
detected by a laser scanner (7, 8).
The paradigm shifting advantages of DNA microarrays were
their highly multiplexed nature and minimal requirements for
sample input, which allowed for an unbiased screen for rele-
vant gene expression. The reproducibility and scalability of DNA
microarrays also allowed for the creation of the Gene Expression
Omnibus, a database repository of all published microarray data
as a rich public resource (9).
Soon after the first DNA microarrays, it was demonstrated that
protein microarrays could similarly be used for the detection of
protein binding molecules, including autoantibodies in the serum
of patients with autoimmune disease (10–14). Protein microar-
rays have been used as powerful tools to sub-classify patients with
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Table 1 | Historical and current techniques for the detection of autoantibodies.
Technique Description Key examples
Radiobinding assay Radioactively labeled antigen is incubated with
serum, and radioactivity in the antibody-binding
fraction is measured
Used in the detection of double-stranded DNA autoantibodies (66) and
insulin autoantibodies (67), although currently less frequently used
due to the requirement of radioactive reagents
Immunohistochemistry A cell line or whole tissue is prepared on a slide and
incubated with serum. Antibody binding is measured
by visualizing fluorescence or enzyme-mediated
color change, usually through the use of a secondary
antibody conjugated to an enzyme or fluorophore
Used in some anti-nuclear antibody (ANA) testing (68), autoimmune
hepatitis testing (69), and in the characterization of anti-citrullinated
protein autoantibodies (70, 71)
Enzyme-linked
immunosorbent
assay (ELISA)
Antigen is coated onto the surface of a multi-well
plate and probed with serum. An
enzyme-conjugated anti-human secondary antibody
is typically used for colorimetric detection
Used in some ANA testing (72), for the sub-classification of
anti-neutrophil cytoplasmic antibodies (73), and for vaccination
serologies
Bead-based assays Antigens of interest are covalently coupled to
color-barcoded beads. Beads are incubated with
serum, washed, and then incubated with a
fluorescent secondary antibody. Fluorescence is
detected using a specialized flow cytometer
Bead-based technology can also be used clinically for detection of
autoantibodies. Recently it has notably been used for the discovery of
anti-cytokine autoantibodies (ACAAs) in the disease Autoimmune
Polyendocrine Syndrome Type I (APS-1) (51, 52) and
immunodeficiency associated with anti-IFN γ ACAAs (50, 74, 75)
Protein microarray See text of this article Widely used in identifying autoantibodies in autoimmune diseases
(10), and recently used to identify ACAAs against B-cell activating
factor (BAFF) in SLE (18) and ACAAs against type I IFNs in patients
with RAG insufficiency
autoimmune diseases (15, 16), to monitor disease activity (17),
and for the discovery of novel autoantibodies (18, 19). Although
protein microarrays can be used to detect many types of molecules
that bind to the printed features (20), in this review we will focus
on protein microarrays for the detection of autoantibodies.
PROTEIN MICROARRAY DESIGN AND IMPLEMENTATION
Protein microarray protocols have been published previously (13,
18, 21, 22). Here, we provide an updated overview of protein
microarray processing. We describe our experience and highlight
different technologies and approaches relevant to protein microar-
rays in immunodeficiency. Detection and analysis of autoantibody
reactivity by protein microarray have three key steps: (i) array
design and fabrication; (ii) array probing, detection, and scanning;
and (iii) image processing and data analysis (Figure 1).
MICROARRAY DESIGN AND FABRICATION
Protein microarrays can be designed and fabricated independently
or purchased commercially. Array fabrication requires a microar-
ray printer, purified antigens of interest (either expressed in the
laboratory or purchased commercially), and a microarray surface
on which to print, typically a specially coated microscope slide.
Antigens are loaded into one or multiple 384 well plates at either
a single concentration or a series of concentrations (our typical
protein printing concentration is 200µg/ml). A typical microar-
ray printer can print on the scale of 100 microarrays over the
course of 1 day.
The choice of surface on which to print should be guided by
the technical requirements of each laboratory and also the chem-
istry of the antigens in question. Technically, some microarray
scanner detectors are located on the opposite side of the laser
source, which precludes the use of opaque microarray surfaces
such as nitrocellulose. The two surfaces with which our lab has the
most experience are nitrocellulose-coated (Maine Manufacturing)
and epoxysilane-coated (SCHOTT) glass slides. The key trade-offs
we have observed are that nitrocellulose has high protein-binding
capacity, but also a high background fluorescence, which can
vary depending on a patient’s serum. Epoxysilane-coated slides
have almost no background fluorescence, which has the advan-
tage of not requiring a background fluorescence subtraction step.
However, this decreased background comes at the expense of a
decreased quantity of protein bound per spot and a corresponding
decrease in signal intensity.
Choice of array surface should also take into consideration the
nature of antigen printed. Nucleic acids, proteins, carbohydrates,
and lipids all have different mechanisms of binding to array sub-
strates. Antigen chemistry should guide array substrate selection,
both for adequate attachment of the molecule to the slide surface
and to preserve the molecule’s structure. Other surfaces in various
stages of development include amine-reactive surfaces, nitrocel-
lulose film coated surfaces (23), plasmonic gold film surfaces
for sensitivity enhancement (24), giant magnetoresistive (GMR)
biosensor-based surfaces for kinetic measurements (25), and sil-
icon surfaces which allow for high-density photolithographic
peptide synthesis (26).
ANTIGEN CONTENT
Over the past decade and a half of protein microarray develop-
ment, significant progress has been achieved in terms of increasing
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FIGURE 1 | (A) Protein microarray technology. Schematic representation
of protein microarrays used for autoantibody detection. Antigens are
printed onto a specially coated microscope slide surface, and serum
antibodies (green) are detected by a fluorescently conjugated secondary
antibody (purple). Microarrays are then scanned, and images are
analyzed using microarray software. Values are calculated for each
antigen based on mean fluorescent intensity and a statistical analysis is
performed. Data can be visualized in a heat map representation.
(B) Simplified schematic representation of proposed map of primary
immunodeficiencies.
sensitivity of detection, the number of features printed on each
microarray, and the diversity of molecules that can be printed.
Initially printed with either nucleic acids or proteins, microarrays
have been extended to profile complex mixtures of nucleic acids,
proteins, peptides (27), lipids (28–30), and carbohydrates (31–33).
Each of these molecules hold their own challenges discussed in the
above references.
For laboratories without microarray printing expertise or
equipment, protein, peptide, lipid, and carbohydrate microarrays
are available from commercial vendors. Commercial microarray
products span a spectrum from highly targeted microarrays with
high coverage of a specific organism or antigen to broader cov-
erage products with the capability to span the entire known pro-
teome. Examples of targeted products include microarrays from
Arrayit onto which key proteins from specific pathogens such as
Plasmodium falciparum or Staphylococcus aureus are printed.
Examples of wide coverage microarray products include the
ProtoArray® from Life Technologies, which includes over 9,000
full length human proteins expressed from cDNA constructs
in an insect expression system (22). Another example of high-
density commercial protein microarrays is peptide microarrays
from PEPperPRINT. PEPperPrint sells both prefabricated or
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custom-printed peptide microarrays fabricated by combinatorial
synthesis using laser printing (34).
Such large-scale screens for autoantibodies are appealing in
theory, but often the vast number of features also comes at the
cost of an increased background signal. Additionally, statistical
correction for multiple observations further diminishes signal, in
comparison to more focused experiments. Cost can also preclude
larger experiments, as prices for each ProtoArray, for example,
are approximately $1,000. Lastly, in these high coverage commer-
cial products, each antigen is not necessarily validated beforehand,
whereas for custom printed arrays, each antigen can be expressed
or purchased and analyzed for quality and activity.
Other high coverage microarrays have been the product of large
academic initiatives, most notably from the Swedish groups associ-
ated with the Human Protein Atlas initiative (35–37). The Protein
Atlas group centered in Stockholm has tightly integrated multiple
proteomic technologies including protein expression and mono-
clonal antibody production, and protein microarrays have been
utilized throughout this process. Another center based at Arizona
State University has developed nucleic acid programmable protein
arrays, in which plasmids are printed on the chip and protein is
expressed cell-free, in situ (38).
Lastly, there are core facilities, laboratories, and companies
which offer printing and processing of microarrays as a send-out
service, most notably from the University of Texas Southwest-
ern Genomics and Microarray Core Facility, which offers a full
printing, processing, and analysis service (16, 39).
MICROARRAY PROBING, DETECTION, AND SCANNING
Probing of microarrays is highly analogous to the probing and
detection of a traditional ELISA. Printed microarrays are blocked
in a blocking buffer to minimize non-specific binding. Serum
is diluted into probing buffer (we typically dilute serum from
immunodeficiency patients at 1:100, while for autoimmune dis-
eases with higher signal intensity we dilute at 1:200). Using these
dilutions, typically only 1–5µl of serum or plasma per patient
is required. Either serum or plasma can be used; however, it is
important to be consistent in the use of either serum or plasma
and to not to use them interchangeably, as there are key discrep-
ancies, particularly among low reactivities, between the two blood
products.
Given the highly multiplexed nature of the assay, care to avoid
confounding factors in processing and analysis is key. Whenever
possible, we run samples on the same day and in parallel. Addi-
tionally, randomizing the order in which controls and samples are
probed aids in minimizing the potential for batch effects, which
can be caused by discrepancies in incubation time lengths.
After probing, microarrays are washed and a fluorescent sec-
ondary antibody is applied. We typically use an IgG Fc-specific
secondary antibody; however, many different isotypes and sub-
classes can be measured through the use of isotype-specific sec-
ondary antibodies. For experiments where comparisons between
isotype abundances are desired, samples can be processed in
replicate, or a multi-color detection scheme can be employed
(40); we typically use the Cy3 and/or Cy5 fluorescence chan-
nels. After incubation with secondary antibodies, the microar-
rays are then washed and dried. Best results are achieved when
microarrays are scanned within 12 h of processing using a fluo-
rescent microarray scanner per manufacturers’ instructions. Care
should be taken to avoid repetitive scans of microarrays to avoid
photobleaching.
IMAGE PROCESSING AND DATA ANALYSIS
High quality microarray images are analyzed using microarray
image processing software. The layout and orientation of anti-
gens on the array are stored in one of multiple file formats, and
loaded into the image software program, which overlays a cor-
responding grid of features over the scanned image. The mean
fluorescent intensity (MFI) of each individual spot, or “feature,”
on the microarray is then exported into a text file. We typically
subtract local background fluorescence, and then average replicate
features.
Normalization of microarray values should be approached with
caution. In ideal settings, we run all samples on the same day to
avoid the potential for normalization artifact. When normaliza-
tion is necessary, median centering is one approach that has been
useful (41). However, this approach operates under the assump-
tion that the median value of each patient is equal, a situation
that under certain circumstances (e.g., highly polyreactive sam-
ples) may not reflect true conditions. In particular, conditions of
hypo- or hyper-gammaglobulinemia can alter these distributions.
Another approach is to print standard features on each array, such
as printing purified IgG or a fluorophore directly onto the array
surface, and to normalize to this set of features. However, there
can be subtle differences in how features are printed, e.g., the con-
centration of an antigen can vary due to evaporation during the
progression of a print run.
A third approach to normalization when batches are run over
multiple days is to use a standard sample with known reactiv-
ity as an internal control. Ratios of values from this one sample
over different days can then be used as a normalization factor.
Taken together, these approaches can be useful normalization tools
when necessary; however, normalization should be approached
with caution as each of these approaches has its own set of
potential confounders.
Post-normalization, statistical differences in autoantibody
reactivities can be assessed using significance analysis of microar-
rays (SAM) (42). SAM is a permutation-based algorithm for
significance testing designed for microarray datasets that is less
conservative than other corrections for multiple comparisons,
such as the Bonferroni correction. In SAM, two or more groups
can be compared, although for immunodeficiency studies it is typ-
ical to compare one immunodeficiency group to healthy controls.
SAM is freely available and can be run either through a script in
the R language or using software such as the Multiple Experiment
Viewer (43). Through SAM, a false discovery rate can be set and
statistically significant autoantibody reactivities identified.
We take the approach that any new result demonstrated by
microarray should be replicated on a second independent plat-
form such as ELISA, western blot, or a bead-based assay. This
approach reduces the potential for platform-dependent artifacts.
Further, platforms like ELISA can be more cost-effective to assess
larger cohorts, after using microarray to identify select candidate
antigens.
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Reproducibility and standardization are critical for any autoan-
tibody assay, and for decades, reference sera have been made
available for standardization within and between institutions (44).
Given new technologies in monoclonal antibody production, these
reference sera can also be replaced with monoclonal antibod-
ies of known affinity and specificity for the antigen of interest.
Such monoclonal preparations have the advantage of being in
infinite supply. Additionally, given the power of new technolo-
gies to discover novel autoantibodies, monoclonal antibodies may
be more readily generated as reference standards than identifying
reference sera. In our laboratory, we use both monoclonal and
serum-based reference standards to ensure reproducibility across
tests.
CURRENT KNOWLEDGE OF THE AUTOANTIBODY
LANDSCAPE IN PRIMARY IMMUNODEFICIENCIES
Given the complex landscape of autoimmunity in immunodefi-
ciency disorders, protein microarrays are a powerful platform to
illuminate new aspects of disease pathophysiology and to identify
novel biomarkers. Currently, relatively little is known about the
full panoply of autoantibodies in primary immunodeficiency.
Most reports have studied individual disease cohorts and evalu-
ated for classical autoantibodies. For example, a recent study found
elevated levels of 12 autoantibodies in patients with DOCK8 defi-
ciency (45). Additionally, cohort studies have found autoantibod-
ies in such immunodeficiencies as immune dysregulation, poly-
endocrinopathy, enteropathy, X-linked (IPEX) (46) and selective
IgA deficiency (47). However, larger scale studies of autoantibody
reactivities in primary immunodeficiencies are lacking.
We recently profiled autoantibody responses in a blinded cohort
of 58 serum samples from healthy individuals and a diverse
set of patients with different immunodeficiencies. Using pro-
tein microarray data alone, we were able to accurately assign
disease based on known anti-cytokine autoantibody reactivi-
ties, validating protein microarray technology for broader use.
To extend these studies, we profiled a cohort of patients with
RAG mutation-associated immunodeficiency and observed the
presence of anti-cytokine autoantibodies (ACAAs) against type
I interferons.
ANTI-CYTOKINE AUTOANTIBODIES
A review of proteomics in immunodeficiency would be incom-
plete without discussion of the burgeoning field of ACAAs, which
have been recently expertly reviewed in Ref. (48, 49). Briefly,
ACAAs have been found to be tightly correlated with a handful
of immunodeficiencies. Perhaps the best described highly sen-
sitive and specific ACAAs include those against interferon γ in
atypical mycobacterial infection or other opportunistic infection
in Southeast Asia (50). A second key example is ACAAs against
type I interferons, which can be observed with or without ACAAs
against IL-17A and IL-22, in Autoimmune Polyendocrine Syn-
drome Type I (APS-1) (51, 52). It is also worth mentioning that
the former study was conducted using luciferase-antigen fusion
proteins while the latter studies utilized a bead-based system for
autoantibody detection. Both of these systems are useful tools with
an intermediate level of depth (10–30 antigens) between protein
microarrays and individual ELISAs.
Utilizing proteomic approaches to study ACAAs has the poten-
tial to be extremely applicable to the study of immunodeficiency on
multiple fronts. First, discovery of novel ACAAs has the potential
to improve our understanding of disease pathophysiology. Sec-
ond, proteomic approaches open up new avenues for biomarker
discovery. Third, they suggest possible therapeutic opportuni-
ties based on cytokine biology. Each of these are active areas of
investigation.
Whenever discussing autoantibodies, and in particular with
regard to ACAAs, a caveat should be placed that the presence
of autoantibodies, even in exquisitely specific patterns, does not
demonstrate that those autoantibodies exert a pathologic effect.
In fact, there are multiple well-studied autoantibodies that are
thought to be markers of disease but do not contribute to the
disease process (53). Direct pathologic effect has perhaps been
most convincingly shown for the role of ACAAs against GM-CSF
in the disease pulmonary alveolar proteinosis, where the cytokine
GM-CSF is integrally involved in the disease process, and passive
transfer of autoantibodies purified from the serum of patients
with the disease reproduces the disease phenotype in non-human
primates (54). Yet for the large majority of described ACAAs, to
assign a pathologic effect is purely speculative, and more research
is needed.
AUTOANTIBODIES IN HEALTHY INDIVIDUALS
To understand autoantibodies in any perturbed state such as dis-
ease, we first need to understand the basal state in healthy individu-
als. Unfortunately, little is known about the prevalence and role of
autoantibodies in healthy individuals’ immune homeostasis. Clin-
ically it is widely appreciated that rheumatologic disease-“specific”
serologies have widely varying levels of specificity (55). The nature
and function of autoantibodies in healthy individuals however is
poorly understood.
Nowhere is this complexity more apparent than in the study
of ACAAs. Multiple studies have found high levels of ACAAs
in healthy individuals, including in preparations of intravenous
immunoglobulin (56–59). While in some diseases certain ACAAs
are specific to a disease, other ACAAs may have variable disease
penetrance, acting in combination with other ACAAs or other fac-
tors to influence disease. More experiments are needed to answer
the questions regarding the prevalence of ACAAs in healthy indi-
viduals and whether ACAAs or programs of ACAAs associate
with specific genotypes or phenotypes. In particular, large ACAA
screens of healthy individuals at different stages of human devel-
opment and under different natural or experimental perturbations
such as vaccination may be highly informative.
DISCUSSION
Protein microarrays, alongside other proteomic technologies, are
valuable tools to define the autoantibody repertoire in primary
immunodeficiency. Essential biological questions still remain to
be answered. What are the complete autoantibody profiles in each
of the primary immunodeficiencies? Are these antibodies patho-
genic, and can they be used as biomarkers for screening, diagnosis,
or disease monitoring? Additionally, the role of autoantibodies
and, in particular, the role of ACAAs in healthy individuals remains
to be elucidated.
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As we learn more about the autoantibody repertoires in differ-
ent diseases, we also will have an opportunity to ask systems-level
questions. As we generate data on hundreds to thousands of
autoantibodies, we can begin to pair these data with other pro-
teomic, genomic, and clinical measurements, hopefully emerging
with models of autoimmune regulation across different states
of immune function. Given the overlap of autoimmunity and
immunodeficiency, these connections may help us better under-
stand both autoimmune and immunodeficiency phenomena.
For example, the immunodeficiency IPEX is caused by muta-
tions in the gene FOXP3. However, there remains a set of
“IPEX-like” patients with autoimmunity and enteropathy. We
are currently using protein microarrays to profile autoantibody
responses in these patients with the hypothesis that sub-groups
may have similar prognoses or similar therapeutic response pro-
files. Another important example is common variable immunod-
eficiency (CVID), the most common primary immunodeficiency
(60). For CVID patients, we have paired autoantibody profil-
ing with genomic and clinical information in order to try to
sub-classify this highly heterogeneous disease.
We envision that given sufficient data sets from individual dis-
eases, one can then map primary immunodeficiency diseases in
a complex multi-dimensional space. The most intuitive of these
approaches would be to map each primary immunodeficiency in a
3-dimensional space of clinical autoimmunity, clinical immunod-
eficiency, and autoantibodies (Figure 1B). However, each of these
axes can be broken down into hundreds or thousands of individ-
ual axes, allowing for bioinformatic analysis to compare across
diseases. Such analysis could shed new light on the diagnosis,
pathophysiology,or treatment of each primary immunodeficiency.
In addition to descriptive profiling studies discussed above,
antibody heavy and light chain cloning technologies allow for the
expression of monoclonal autoantibodies for use in mechanistic
experiments (61–64). Purified monoclonal antibodies allow for
in vitro and in vivo experiments to test the necessity and suffi-
ciency of an antibody for a given phenotype. Once monoclonal
antibodies are isolated, protein microarrays can again be used to
identify a cognate antigen or antigens.
Lastly, given the growing role of autoantibodies and ACAAs
in immunodeficiency, protein microarrays have the potential as
diagnostics in the clinic (65). A single microarray chip can screen
for several autoantibodies important in both rheumatologic and
immunodeficiency disorders. In complex patients with unknown
diagnoses, such a chip could fill a significant clinical diagnostic
need. In summary, protein microarrays have utility and promise
in the field of primary immunodeficiency from basic research
through clinical application.
METHODS
The search terms “Autoantibodies and Immunodeficiency” and
“Protein Microarray” were queried in the following databases:
Pubmed, Scopus, Google Scholar, Stanford University Lane
Library, and Web of Science.
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